Vasomotor Symptoms of Menopause Market Overview
The vasomotor symptoms of menopause market size is estimated to reach $1.8 billion by 2027. Furthermore, it is poised to grow at a CAGR of 7.5% over the forecast period of 2022-2027. The vasomotor symptoms occur in females when their estrogen and progesterone levels start falling. Moreover, the symptoms can develop when the transition from perimenopause starts taking place and right before menopause hits one. Additionally, they are caused due to constriction or dilation of blood vessels. Since the hormonal fluctuation starts taking place, women might experience hot flashes, night sweats, heart palpitation, and lastly, blood pressure changes. Doctors can recommend various courses to treat such symptoms. For example, while going for the anti-depressant course, a doctor might recommend venlafaxine and fluoxetine. The following medication acts to ease nerve pain and other ailments. However, if the course of action is hormonal therapy, OTC hormones drugs can be taken to modify and replenish the falling estrogen and progesterone successfully. The increasing awareness around the availability of such medications and key developments across the pharmaceutical sectors are some of the factors driving the vasomotor symptoms of the menopause industry forward in the projected period of 2022-2027.
Vasomotor Symptoms of Menopause Market Report Coverage
The report: “Vasomotor Symptoms of Menopause Market Forecast (2022-2027)”, by Industry ARC covers an in-depth analysis of the following segments of the vasomotor symptoms of the menopause market.
By Therapy Type- Hormonal and Non-Hormonal.
By Distribution Channel- Hospital Pharmacy, Online Pharmacies, and Retail Pharmacy.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), and Rest of the World (the Middle East, and Africa).
- Geographically, North America’s vasomotor symptoms of the menopause market held a dominant share. It is owing to the robust medical infrastructure, and the government’s substantial undertakings to provide better medical facilities. Additionally, the region has some prominent pharmaceutical market leaders which make the region’s clientele established and evolving. However, Asia-Pacific is set to grow at a lucrative growth owing to the rising awareness around controlling medications and pharmaceutical companies to off-shore production facilities in the following region.
- The awareness around the presence of pain-relieving medication is one of the market drivers. However, side effects post-consumption of certain medications can impede market growth and penetration.
- A detailed analysis of the strengths, weaknesses, opportunities, and threats will be provided in the vasomotor symptoms of the menopause market report.
Vasomotor Symptoms of Menopause Market- By Geography as (%) for 2021.
For more details on this report - Request for Sample
Vasomotor Symptoms of Menopause Market Segmentation Analysis- By Therapy Type
The vasomotor symptoms of the menopause market based on therapy type can be further segmented into hormonal and non-hormonal. Hormonal therapy held a dominant market size in the year 2021. Additionally, the hormonal treatment is further bifurcated into estrogen, progestogen, and combination. The combination of hormonal therapy is being widely used and recommended to patients suffering from vasomotor symptoms. Moreover, researchers have found a 6x increase in the cases where only estrogen was given. Hence both the hormonal therapeutics were infused in a single drug to offer lower chances (15-20%) of ever developing cancer (breast and ovarian). However, non-hormonal therapy is estimated to be the fastest-growing with a CAGR of 8.7% over the forecast period of 2022-2027. It is owing to the range of drugs that are now being discovered, which a=can alternatively be used to treat cases of hot flashes etc. For example, oxybutynin, a drug, was covertly used in treating overactive bladder. Only lately, after the researchers found its alternative use in treating hot flashes in the woman. Other SSRI drugs are regularly being studied and evaluated for their use in treating vasomotor symptoms.
Vasomotor Symptoms of Menopause Market Segmentation Analysis- By Distribution Channel
The vasomotor symptoms of the menopause market can be further segmented into Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The hospital pharmacy held a dominant market share in the year 2021. It is owing to the availability of predominant drugs in the hospital pharmacy and the need for prescriptions to purchase such drugs. However, the online pharmacies segment is estimated to be the fastest-growing, with a CAGR of 8.3% over the forecast period of 2022-2027. It is owing to the recent advent of online pharmacies. Moreover, there is a ready discount available on such platforms. For example, Tata 1 MG has a scheme that offers a flat discount of up to 20% by purchasing allopathic drugs; additionally, a user gets an additional 5% discount if they upload their doctor’s prescription. The following models will help the online pharmacy to grow.
Vasomotor Symptoms of Menopause Market Segmentation Analysis- By Geography
The vasomotor symptoms of the menopause market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant share of 39% as compared to the others in 2021. It is owing to the availability of ready knowledge regarding the availability of drugs helping to relieve the symptoms of such cause; moreover, up to 75% of the females in the USA experience hot flashes around the time of menopause. Additionally, the age at which the following symptoms start to show is around 52 years. Furthermore, pharmaceutical giants such as Pfizer and others have a stronghold over the region and regularly campaign regarding the availability and the use of such drugs. However, Asia Pacific is set to offer lucrative growth opportunities to marketers. It is owing to the rising knowledge of women and the various campaign regarding the awareness of such symptoms and their ready treatments. Furthermore, menopause’s stigma has been widely removed across the regions, as it is advocated as a natural aging phenomenon than an illness. The following has helped and will help in the ready adoption of drugs and medications. Additionally, the woman’s menopause age in countries like India is far lower than their western counterparts. As observed, the average age for the same is 46.2 years, less than the global average of 51 years.
Vasomotor Symptoms of Menopause Market Drivers
The increasing prevalence of female smokers and its direct link to hormonal imbalance will positively affect the market.
The tobacco industry has aligned its strategies to target the category of female smokers. Global advertisements have aligned smoking with independence, modernity, glamor, and even stress relief. The availability of “light” cigarettes is a prime example of how tobacco companies have tapped the market. Moreover, various researchers have attributed smoking to early menopause and hormonal imbalances. Smoking has been considered anti-estrogenic and additionally has aligned that progesterone and estrogen levels substantially decrease in the mid-40s and smoking further decreases the ratio. For example, Russia’s female smoking prevalence is 22.80%. Additionally, the gap between female and male smokers in North America is less than 4%. The following market trends will help fuel the demand for the following market.
The advent and adoption of hormonal therapeutic medications have contributed to the growth of the market.
Estrogen therapy, a type of hormonal therapeutic treatment has shown great results for women experiencing hot flashes. Moreover, the results from various studies have shown that the symptoms get elevated by up to 35-40% post including the hormonal therapy medication. Moreover, the results showed that low-dose oral and transdermal estrogen in all dose ranges was more likely than placebo to decrease the frequency of VMS (Vasomotor Symptoms). Furthermore, the nanostructured formulation was safe and effective in relieving the symptoms of menopause. Lastly, the mean daily decrease in the number of hot flashes from baseline was found in the studies. The following factors would help in the growth and deeper penetration of the market.
Vasomotor Symptoms of Menopause Market Challenges
The side effects of post-consumption of medication have reported ill effects on one’s health.
The use of hormonal therapies amongst women has had severe repercussions. For example, if the combination of estrogen and progesterone is given, it increases the chances of developing breast cancer by up to 75%. Moreover, there are chances that the cancer is set at a later stage, and hence the fatality is significantly high. Additionally, it is reported the more prolonged the therapy lasts, the more severe the disease gets. Furthermore, if “estrogen” based hormonal therapy is taken, then the chances of developing breast cancer reduce, although they can develop if the therapy has lasted for more than ten years. Moreover, the following can induce ovarian cancer.
Vasomotor Symptoms of Menopause Industry Outlook
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the vasomotor symptoms of the menopause market. The top 10 vasomotor symptoms of menopause market companies include:
- Eli Lilly and Company
- Procter & Gamble
- Pfizer Inc.
- Ausio Pharmaceuticals LLC
- EndoCeutics Inc.
- Novartis AG
- Merck KGaA
- Emcure Pharmaceuticals
- Glenmark Pharmaceuticals
- Edgemont Pharmaceuticals
- In February 2022, Cleveland Clinic announced the top 10 medical innovation for 2022, the breakthrough technologies helps the healthcare market in a broader sense. Out of the ten, one of the innovations was linked to hot flashes being faced by menopausal women. a new group of non-hormonal drugs, called NK3R antagonists, have emerged as a viable alternative to hormone therapy. These drugs disrupt a signaling pathway in the brain that has been linked to the development of hot flashes and have shown promise in clinical trials for relieving moderate to severe menopausal hot flashes as effectively as hormones.
- In January 2021, Oxybutynin showed positive results in the treatment of menopausal women. Moreover, researchers showed that the drug reduces the cases of hot flashes by up to 77%. Patients who received a placebo had a 27% reduction in hot flashes, compared with an 86% reduction in patients treated with higher-dose oxybutynin (P < .01) and about a 70% reduction in patients treated with lower-dose oxybutynin (P < .01 for both doses vs placebo).
- In January 2021, Neurokinin 3 Receptor Antagonist, a potential drug showed efficacy up to 75% in preventing hot flashes post 48 hours of consumption. Moreover, it is not a hormonal therapy drug.